NCT02819752 2026-04-09
PEACH
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
Clinical Trials
136 trialsNCT03983668 2026-03-30
CMP-001 for Relapsed and Refractory Lymphoma
University of Iowa
Phase 1/2 Terminated
NCT03386357 2026-03-27
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Erlangen-Nürnberg Medical School
Phase 2 Terminated
NCT05036681 2026-03-27
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05204290 2026-03-24
Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab
Wake Forest University Health Sciences
Phase EARLY_PHASE1 Terminated
NCT05059470 2026-03-23
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04777851 2026-03-09
REPLACE
Translational Research in Oncology
Phase 3 Terminated
NCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT04268277 2026-02-27
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Phase 2 Terminated
NCT03990961 2026-02-20
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
University of Chicago
Phase 2 Terminated
NCT03559049 2026-02-12
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT03237572 2026-02-09
Breast-48
University of Virginia
Phase 1 Terminated
NCT04166734 2026-02-04
MESO-PRIME
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT03436056 2026-01-29
PRIMING
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT04557007 2026-01-29
Oncomabs
Oslo University Hospital
Terminated
NCT04856189 2026-01-29
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
University of California, Davis
Phase 1/2 Terminated
NCT04095689 2026-01-23
INTEGRAL
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT04862455 2026-01-23
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06006923 2026-01-20
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
University of Pittsburgh
Phase 2 Terminated
NCT03844750 2025-12-31
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
University of California, San Francisco
Phase 2 Terminated
NCT03225547 2025-12-23
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
University of Chicago
Phase 2 Terminated
NCT03260504 2025-12-08
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
University of Washington
Phase 1 Terminated
NCT03595683 2025-12-08
Pembrolizumab and EDP1503 in Advanced Melanoma
University of Chicago
Phase 2 Terminated
NCT04955743 2025-11-24
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
NCT02706353 2025-11-21
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT03498612 2025-11-12
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
University of Washington
Phase 2 Terminated
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT06046482 2025-10-22
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05263492 2025-10-02
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT03307759 2025-09-15
SABRseq
Peter MacCallum Cancer Centre, Australia
Phase 1 Terminated
NCT03347617 2025-09-09
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT03769532 2025-08-24
PEMAZA
Technische Universität Dresden
Phase 2 Terminated
NCT02892201 2025-07-29
Pembrolizumab in HNSCC With Residual Disease After Radiation
Yale University
Phase 2 Terminated
NCT05691829 2025-07-29
IRRADIATE-Lung
NYU Langone Health
Phase 2 Terminated
NCT03316872 2025-07-25
Study of Pembrolizumab and Radiotherapy in Liver Cancer
University Health Network, Toronto
Phase 2 Terminated
NCT04729348 2025-07-25
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
Massachusetts General Hospital
Phase 2 Terminated
NCT04904185 2025-07-25
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Herlev Hospital
Phase 1 Terminated
NCT03401853 2025-07-22
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
University of Washington
Phase 2 Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT05756166 2025-06-24
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT05634577 2025-06-19
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03325101 2025-06-12
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Mayo Clinic
Phase 1/2 Terminated
NCT04789096 2025-06-06
TUGETHER
Breast Cancer Trials, Australia and New Zealand
Phase 2 Terminated
NCT06140407 2025-06-05
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT04251169 2025-06-03
TATEN
SOLTI Breast Cancer Research Group
Phase 2 Terminated
NCT04849364 2025-05-31
PERSEVERE
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated